CHF Solutions Inc., (NASDAQ: CHFS) presented at The South Florida Stock & Bond clubat the Boca Raton Country Club on
Tuesday, February 27, 2018. About CHF Solutions: Formerly Sunshine Heart, CHF Solutions, Inc. (NASDAQ:CHFS) is an Eden Prairie, MN early-stage medical device company focused on commercializing the Aquadex FlexFlow Aquapheresis System. The Aquadex FlexFlow Aquapheresis System, is indicated for temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF is headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
· February 2018 - CHF Solutions, Inc. strengthens sales force with the appointment of Richard E. Roberts as its Senior Director of U.S. Sales, who will lead the US sales force for the company’s Aquadex FlexFlow System.
· January 2018 - CHF Solutions, Inc. commences in-house manufacturing of aquadex flexflow console and blood circuits.
· January 2018 – CHF Solutions, Inc. appoints Vitaliy Epshteyn Vice President of Operations and Engineering
· December 2017 - CHF Solutions signs international distribution and services agreement with Singapore-based TRANSMEDIC Pte Ltd.
· November 2017 - CHF Solutions, Inc. announced the closing of $18.0 Million underwritten Public Offering of Series F convertible preferred stock, together with warrants, for gross proceeds of $18.0 million.
Q3 results for the period ending September 30, 2017:
· CHF Solutions, Inc. announced 21% revenue growth which included the following highlights:
· Revenue for third quarter ended September 30, 2017 increased 21% compared to the same period in 2016 on a proforma basis.
· Hired and trained 6 additional experienced sales professionals and increased the US sales team to 10 territories, up from 4 territories in Q2.
· Initiated international distribution by signing a distribution agreement with APC Cardiovascular Ltd., a distributor based in the United Kingdom.
· Held a scientific advisory board meeting with 6 key physician opinion leaders that provided guidance on protocol design for a mechanistic study and a registry study expected to begin in early 2018.
· Transition of Aquadex FlexFlow System manufacturing from Baxter to in-house operations going as planned and on schedule. In-house manufacturing expected to commence in the fourth quarter of 2017.
· Reduced operating expenses by 31% and operating cash utilization by 35% from same quarter last year.
· Subsequent to quarter end, received NASDAQ notification that Company is in compliance with minimum bid price requirements and the listing matter has been closed. For more information please visit: http://ir.sunshineheart.com .
ABOUT YOUR PRESENTER: Claudia Napal Drayton, Chief Financial Officer. Claudia Drayton joined CHF Solutions in January of 2015 as Chief Financial Officer. Ms. Drayton spent the prior 15 years at Medtronic, Inc., a global leader in the medical device industry. During her tenure, she held multiple senior managerial finance positions in Medtronic’s Corporate Finance organization and its Cardiac Rhythm Management division, culminating with a two year assignment in Europe serving as Chief Financial Officer of the Peripheral Vascular Business and most recently, as Chief Financial Officer and Senior Finance Director of the Integrated Health Solutions business. In these capacities her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, business integrations and implementation of financial best practices.
Before Medtronic, Ms. Drayton was an Audit and Business Advisory Manager at Arthur Andersen for seven years. She is a certified public accountant, graduated with a BS in Accounting from the University of Mary Hardin-Baylor and holds an MBA from the University of Minnesota’s Carlson School of Management.
Altimmune, Inc. (NASDAQ:ALT) presented at the Boca Raton Country Club on Tuesday, December 12, 2017.
About Altimmune - Immunotherapeutics for a Better Tomorrow: Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.
Recent Corporate Highlights: Initiated a proof-of-concept Phase 2 Flu vaccine clinical trial with the Company’s first-in-class NasoVAX™ vaccine, with initial data expected in 1Q-2018. Completed enrollment in the Company’s HepTcell™ immunotherapeutic Phase 1 clinical trial against hepatitis B, with topline data expected in 4Q-2017. Remained on track to initiate a BARDA-funded Phase 1 trial with NasoShield™, a next-generation intranasal, single-dose, anthrax vaccine in the first quarter of 2018, with topline data anticipated in the second quarter of 2018.
Remained on track to initiate a key pre-clinical bridging study with SparVax-L™, a lyophilized anthrax vaccine, in the fourth quarter. The study is fully-funded by NIAID. Closed a Series B preferred stock offering, raising approximately $13.0 million in net proceeds
ABOUT YOUR PRESENTER. Bill Enright - Chief Executive Officer. Mr. Enright currently serves as our President and CEO and is a member of our board of directors. He was first elected to our board of directors in June 2008. Mr. Enright brings more than 25 years of experience in a variety of positions within the life science and biotech industries. Prior to joining Altimmune, Mr. Enright spent six years with GenVec, Inc. (NASDAQ: GNVC) with increasing responsibilities culminating in the Head of Business Development. Mr. Enright was responsible for helping to build GenVec’s vaccine business including generating approximately $140 million of funding for vaccine-related initiatives and moving four vaccines into clinical development. Prior to GenVec, Mr. Enright was a self employed consultant providing business development and strategic marketing services to academic institutions and a number of small to mid-size life science companies. Prior to becoming a consultant, and after spending several years as a bench scientist at SUNY at Buffalo, Mr. Enright spent 12 years with Life Technologies, Inc., working in various licensing, business management, manufacturing and research roles. Mr. Enright received a Master of Arts in Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.
Piedmont Lithium Ltd (ASX-PLL, NASDAQ-INTERNATIONAL-PLLLY) presented at The Stock & Bond CLub November 30, 2017. The company holds a 100% interest in the Piedmont Lithium Project ("Project") which is located within the world-class Carolina Tin-Spodumene Belt ("TSB"), and along trend to the Hallman Beam and Kings Mountain mines, historically providing most of the western world's lithium between 1950 and 1990. The TSB is one of the premier localities in the world to be exploring for lithium pegmatites given its history of lithium bearing spodumene mining, favorable geology and ideal location with easy access to infrastructure, power, R&D centers for lithium and battery storage, major high-tech population centers and downstream lithium processing facilities.
The TSB has previously been described as one of the largest lithium provinces in the world and is located approximately 40 kilometers west of Charlotte, North Carolina, United States. The TSB was the most important lithium producing region in the western world prior to the establishment of the brine operations in Chile in the late 1990's. The TSB extends over approximately 60 kilometers in length and reaches a maximum width of approximately 1.6 kilometers.
The Project was originally explored by Lithium Corporation of America which eventually was acquired by FMC Corporation ("FMC"). FMC and Albemarle Corporation ("Albemarle") both historically mined the lithium bearing spodumene pegmatites from the TSB with the historic Kings Mountain lithium mine being described as one of the richest spodumene deposits in the world by Albemarle. These two mines and their respective metallurgy also formed the basis for the design of the two lithium processing facilities in the region which were the first modern spodumene processing facilities in the western world.
Albemarle and FMC continue to operate these important lithium processing facilities with FMC's Bessemer City lithium processing facility being approximately 14 kilometers from the Project whilst Albemarle's Kings Mountain lithium processing facility is approximately 17 kilometers from the Project.
The Company is in a unique position to leverage its position as a first mover in restarting exploration in this historic lithium producing region with the aim of developing a strategic, U.S. domestic source of lithium to supply the increasing electric vehicle and battery storage markets. For further information, please visit: www.piedmontlithium.com
ABOUT YOUR PRESENTER: Mr. Anastasios (Taso) Arima. Executive Director Mr. Arima is a resource company executive with a strong history of identifying company-making resource projects. He has extensive experience in the formation and development of resource projects in North America. Mr. Arima is currently Executive Director of Paringa Resources Ltd., which is developing a coal project in the U.S., and formerly Executive Director of Coalspur Mines Ltd.., which is developing a coal project in Canada, and Prairie Mining Ltd., which is developing a coal project in Poland. Mr. Arima was instrumental in the identification and acquisition of all of Paringa’s and Coalspur’s projects, as well as the corporate strategy and marketing of the companies. Mr. Arima began his career as a resources analyst for a Perth based boutique investment banking firm where he specialized in assessing the technical and financial aspects of resource companies and their projects. He has previously worked in the hydrocarbon division at
Worley Parsons Limited. He attended the University of Western Australia where he earned a Bachelor of Commerce and a Bachelor of Engineering. Mr. Arima was appointed a Director of the Company on 1 October 2016.
Nephros presented at Stock & Bond Club: Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Nephros filters or ultrafilters are used primarily in medical applications in various settings. These ultrafilters are used by dialysis centers for assisting in the added removal of biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and the patients. Additionally, Nephros ultrafilters are used in hospitals and medical clinics for added protection in retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water. These ultrafilters provide barriers that assist in improving infection control with showers, sinks, and ice machines. For more information please visit https://www.nephros.com
ABOUT YOUR PRESENTER: Daron Evans – President & CEO. Mr. Evans joined the company as President and CEO in April 2015, and has served on Nephros’ board of directors since 2013. He is a life sciences executive with over 20 years of financial leadership and operational experience. Mr. Evans was recently Managing Director of PoC Capital, LLC, and is a member of the board of Zumbro Discovery, Inc., an early stage company developing a novel therapy for resistant hypertension. From 2007 to 2013, Mr. Evans was Chief Financial Officer of Nile Therapeutics, Inc., a development-stage cardiovascular company that merged with Capricor Therapeutics, Inc. (NASDAQ:CAPR) in 2013. From 2004 to 2007, he held various project management and performance improvement roles at Vistakon Inc. and Scios, Inc., both divisions of Johnson & Johnson Corp. Mr. Evans was a co-founder of Applied Neuronal Network Dynamics, Inc. and served as its President from 2002 to 2004. From 1995 to 2002, Mr. Evans served in various roles at consulting firms Arthur D. Little and Booz Allen & Hamilton. Mr. Evans received his Bachelor of Science in Chemical Engineering from Rice University, his Master of Science in Biomedical Engineering from a joint program at the University of Texas at Arlington and Southwestern Medical School and his MBA from the Fuqua School of Business at Duke University.
Dthera Sciences (OTCQB: DTHR) and Sonoma Pharmaceuticals (NASDAQ: SNOA) presented n Tuesday, October 17, 2017. About Dthera Sciences: Dthera Sciences, based in San Diego, CA, is a digital therapeutics company focused on developing innovative digital 'quality of life' therapies for neurodegenerative diseases and oncology. The Company's lead product, ReminX, is an artificial-intelligence-powered digital therapeutic designed to reduce anxiety and improve quality of life in patients with Alzheimer's disease and Dementia. For more information, please visit www.dthera.com and www.reminx.com
Digital Therapeutics is a new subsection of digital health that strives to directly deliver a therapy via use or interaction with software technology. The goal of Digital Therapeutics is to mirror an effective treatment and use technology to scale it to a larger patient population, thereby amplifying doctors' and nurses' care, changing patient behavior, and most importantly, reducing cost of care.
Alzheimer's disease is the 6th leading cause of death in the United States. Currently, more than 5 million Americans are living with Alzheimer's disease in the United States alone. In 2017, the direct cost to American society of caring for those with Alzheimer's disease and other dementias will total an estimated $259 billion.
Reminiscence Therapy is an established treatment for Alzheimer's disease that involves reviewing and discussing recognizable memories with patients, typically by looking at photos, and hearing or discussing the familiar stories related to them. Reminiscence Therapy has been in use for nearly 30 years and has proven to be very effective at reducing anxiety and increasing the overall Quality of Life (QoL) in Alzheimer's disease and Dementia patients in numerous clinical trials.
About Sonoma Pharmaceuticals, Inc.Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com
According to BCC Research, skin conditions are among the most common health problems among most national populations, collectively exceeding the prevalence of conditions such as obesity, hypertension and cancer. The considerable costs of skin diseases include physician visits, hospital care, prescription drugs and over-the-counter products for treating or managing these conditions, as well as indirect costs due to productivity losses.
The global market for skin disease treatment technologies, which reached $17.1 billion in 2015, should reach $20.4 billion in 2020, demonstrating a five-year compound annual growth rate (CAGR) of 3.6%. The U.S market for skin disease treatment, which dominates the global market throughout the period, totaled $7.5 billion in 2015 and should reach $8.6 billion in 2020, reflecting a five-year CAGR of 2.6%.
ABOUT YOUR PRESENTERS: Edward Cox, CEO, Dthera Sciences: Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox served as the President, Director and Secretary of Bio-Quant, Inc. from January 2007 until BioQuant’s merger with NexMed, Inc., which was renamed Apricus Biosciences. Prior to 2007, Mr. Cox previously served as an executive or board member of both public and private companies in the areas of Healthcare, Life Science, Technology and Resources. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.
Robert Miller, Chief Financial Officer, Sonoma Pharmaceuticals, Inc. Robert Miller has served as our chief financial officer since June 2004 and was a consultant to us from March 2003 to May 2004. Mr. Miller has served as a director of Scanis, Inc. since 1998 and served as acting chief financial officer from 1998 to June 2006. He was a chief financial officer consultant to Evit Labs from June 2003 to December 2004, Wildlife International Network from October 2002 to December 2005, Endoscopic Technologies from November 2002 to March 2004, Biolog from January 2000 to December 2002 and Webware from August 2000 to August 2002. Prior to this, Mr. Miller was the chief financial officer for GAF Corporation, Penwest Ltd. and Bugle Boy and treasurer of Mead Corporation. He received a B.A. in economics from Stanford University and an M.B.A. in finance from Columbia University.Ilan Danieli, CEO has served as Precipio's CEO since founding the company in early 2011. With over 20 years managing small and medium-size companies, some of his previous experiences include COO of Osiris, a publicly-traded company based in New York City with operations in the US, Canada, Europe and Capital Management, a multi-billion-dollar hedge fund; and in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar-Ilan University in Israel.
Aethlon Medical Inc. (NASDAQ: AEMD) presented at The South Florida Stock & Bond Club on Wednesday, June 28, 2017.
Aethlon Medical creates immunotherapeutic medical technologies to address unmet needs in global health and biodefense to combat infectious disease and cancer. The Aethlon Hemopurifier® is a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. The device has been validated to capture Ebola, Zika, Lassa, MERS-CoV, HIV, Hepatitis C, Cytomegalovirus, Epstein-Barr, Herpes Simplex, Chikungunya, Dengue, West Nile, Smallpox related viruses, H1N1 Swine Flu, H5N1 Bird Flu, and the reconstructed Spanish flu virus of 1918. The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study. Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.
Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). ESI's TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals. Note: Of the hundreds of viruses that are infectious to humans, only 9 are addressed with an approved antiviral drug agent. Compounding this therapeutic challenge are the three to four new viruses that are discovered to be infectious to humans each year. To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV). In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."
Concluded an FDA-approved feasibility study to advance the Hemopurifier® as a broad-spectrum countermeasure against bioterror and pandemic threat viruses. The Company disclosed plans to submit an Expedited Access Pathway (EAP) program application to the FDA. The Company announced that its Exosome Sciences diagnostic subsidiary will conduct a follow-on study related to Chronic Traumatic Encephalopathy (CTE) in former NFL players.
ABOUT YOUR PRESENTER: James A. Joyce, Chairman and Chief Executive Officer. James A. Joyce founded Aethlon Medical in May 1998, and presently serves as Chairman, President and Chief Executive Officer. During Mr. Joyce's tenure, Aethlon has evolved the concept of a medical device to treat infectious disease into a reality of treating infected patients in a clinical trial environment. The resulting Hemopurifier® technology is positioned to treat global pandemic issues such as HIV/AIDS, Hepatitis-C, and pathogens most likely to be weaponized for use in bioterrorism. Mr. Joyce has been an active participant in the emerging biodefense industry. He has testified before Congress on issues related to Project BioShield legislation and the deployment of the Hemopurifier as a countermeasure against biological weapons. His efforts have been instrumental in expanding the definition of treatment countermeasure in Project BioShield legislation to include medical devices. Mr. Joyce recently served on the Project BioShield panel at the Federal Biodefense Research Conference, and was named Co-Chairman of the Bioterrorism/Chemical and Nuclear Security Task Force of the Homeland Security Industries Association. Mr. Joyce actively discusses issues related to infectious disease at various conferences, and has been featured in news stories on CNN, NBC, ABC, and other media outlets. From February 1993 until founding Aethlon Medical, Mr. Joyce was Chief Executive Officer of James Joyce & Associates. Previously, he was founder and Chief Executive Officer of Mission Labs, Inc., was a principal at London Zurich Securities, Inc., and played professional football for the Denver Broncos of the National Football League. Mr. Joyce is a graduate of the University of Maryland.
The Geo Group (NYSE: GEO) presented on Thursday, June 22, 2017 at The Boca Raton Country Club!
COMPANY OVERVIEW: The GEO Group, Inc. (NYSE: GEO) is the first fully integrated equity real estate investment trust specializing in the design, financing, development, and operation of correctional, detention, and community reentry facilities around the globe. GEO is the world's leading provider of diversified correctional, detention, community reentry, and electronic monitoring services to government agencies worldwide with operations in the
United States, Australia, South Africa, and the United Kingdom. GEO's worldwide operations include the ownership and/or management of 143 facilities totaling approximately 100,000 beds, including projects under development, with a growing workforce of approximately 23,500 professionals. FIRST QUARTER 2017 HIGHLIGHTS: GEO reported total revenues for the first quarter 2017 of $550.6 million up from $510.2 million for the first quarter 2016. Net Income Attributable to GEO of $0.35 per Diluted Share. Adjusted Net Income of $0.37 per Diluted Share. Net Operating Income of $142.4 million. Normalized FFO of $0.51 per Diluted Share. AFFO of $0.65 per Diluted Share.
ABOUT YOUR PRESENTER: Pablo E. Paez, Vice President, Corporate Relations . Mr. Paez joined GEO 14 years ago and has headed GEO’s Investor Relations department since. He has been involved in heading their investor relations and communications functions in connection with every major equity offering, financing transaction, acquisition, and other corporate actions since 2003. This includes three follow on equity offerings, close to a dozen debt financing or refinancing transactions, six major company acquisitions in addition to smaller asset purchases, and GEO's REIT conversion in 2012/2013. As Vice President of Corporate Relations, since 2010, he oversees all of GEO's investor relations and outside communications functions including media and public relations. He is the primary point of contact at GEO for the Buy Side and Sell Side. He also serves as GEO's private charitable foundation's Executive Director and as Chairman of GEO's Political Action Committee. Mr. Paez holds Bachelors (majoring in Finance) and MBA degrees from Florida Atlantic University (FAU) and currently serves as Chairman of the FAU Alumni Association Board of Directors. He has resided in Palm Beach County since 1999.
The South Florida Stock & Bond Club Proudly Presents:
Legacy Education Alliance Inc., (OTCQB: LEAI) at the Boca Raton Country Club on Tuesday, March 21, 2017.
COMPANY OVERVIEW: Legacy Education Alliance is a leading provider of practical, high-quality, and value-based educational training on the topics of personal finance, entrepreneurship, real estate and financial markets investing strategies and techniques. Their programs are offered through a variety of formats and channels, including free-preview workshops, basic training classes, symposiums, telephone mentoring, one-on-one mentoring, coaching and e-learning, primarily under the Rich Dad® Education brand (Rich Dad) which was created in 2006 under license from entities affiliated with Robert Kiyosaki, whose teachings and philosophies are detailed in the book titled, Rich Dad Poor Dad. In addition to Rich Dad, Legacy markets their products and services under a variety of brands, including The Independent Woman, Women in Wealth, Brick Buy Brick - Martin Roberts and Elite Business Star. Their products and services are offered in the United States, Canada, the United Kingdom, and other international markets. Legacy Education Alliance is a global company, with approximately 200 employees, founded in 1996, and through a reverse merger, became a publicly-held company in November 2014. The Company has cumulatively served more than two million students from more than 150 countries and territories over the course of our operating history. Recent highlights for the company include:
Q3 2016 revenue of $22.5 million, with net-income of $1.2 million or $.05 per basic and diluted common share Revenue of $69M for 9 Months ended Sept. 30, 2016 vs $67M same period 2015.
Net Income $2.8 million or $0.13 per basic common share for 9 Months ended Sept. 30, 2016 vs net loss of ($2.6) million or ($0.12) per basic and diluted common share for same 2015 period Strong Cash position with minimal debt. LEAI trades at a discount to other publicly-traded companies in education industry. Strong Management Team and Board of Directors/Significant growth opportunities globally.
ABOUT YOUR PRESENTER: CHRISTIAN BAEZA
Executive Vice President and Chief Financial Officer.
Mr. Baeza joined Legacy Education Alliance in April 2015. Prior to joining the company, Mr. Baeza held various senior finance positions including Director of Financial Reporting and Assistant Corporate Controller at Kraton Performance Polymers, Inc. From 2003 to 2008 he held various finance positions at Spectra Energy Corporation. Mr. Baeza began his career as a member of the accounting and auditing practice at Arthur Andersen LLP from 1995 to 1998. Mr. Baeza earned his B.B.A. degree in accounting from Florida International University.
OpGen, Inc., (NASDAQ: OPGN) at the Boca Raton Country Club
on Wednesday, February 15, 2017
COMPANY OVERVIEW: Complete Solutions for Microbial Genetic Analysis - OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. OpGen is dedicated to positively influencing individual healthcare outcomes, enhancing public health, and advancing scientific research by delivering precise, actionable information and results. We offer comprehensive multi-parameter screening and surveillance panels to combat current and emerging multi-drug resistant organisms (MDRO) including carbapenem resistant enterobacteriaceae (CRE) with the next generation of diagnostic and epidemiologic solutions. Learn more at www.opgen.com. OpGen, Acuitas MDRO, Acuitas Lighthouse and QuickFISH are registered trademarks of OpGen, Inc.
ABOUT YOUR PRESENTER: Timothy Dec, CFO. Mr. Dec, has more than 20 years of public company financial leadership experience in technology and healthcare companies. He has served in chief financial officer or other senior financial executive roles at companies in a number of industries, including three publicly traded companies listed on NASDAQ or AMEX, such as Corvis Corporation, and at private equity-backed companies. Prior to joining OpGen, Mr. Dec served as Senior Vice President and Chief Financial Officer for Clubwidesports, LLC, a start-up sports management software company, from January 2014 to April 2015. From August 2007 to December 2012, he was Senior Vice President and Chief Financial Officer of Fortress International Group, Inc., a publicly traded company. Mr. Dec also has public accounting firm experience. He is an adjunct professor at Mount St. Mary’s University in Emmitsburg, Maryland, where he teaches M.B.A. courses in Finance. Mr. Dec holds a B.S. in accounting from Mount Saint Mary’s University, and an M.B.A. from American University in Washington, DC.
OWC Pharmaceuticals Research Corp. (OTCQB: OWCP) presented
at the Boca Raton Country Club on Wednesday, February 1, 2017
COMPANY OVERVIEW: OWC Pharmaceutical Research Corp. [OTCQB: OWCP] is engaged in the business, through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., of conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development of cannabis-based products and treatments specifically designed for Multiple Myeloma, Psoriasis, Fibromyalgia, PTSD, Migraines, and unique delivery systems. These include a Cannabis Sublingual Tablet and a Cannabis Based Psoriasis Topical Cream.
ABOUT YOUR PRESENTER:
Ziv Turner, VP Sales and Business Development OWC Pharmaceutical Research Corp and Managing Director of One World Cannabis Ltd. Mr. Turner is a proven entrepreneur with extensive business development expertise, as well as significant experience within the international business community. A successful engineer, Mr. Turner has 20 years’ experience working in senior management positions for leading telecom companies.
Beginning 1995, he was head of sales for various leaders in the telecommunication industry. His responsibilities included establishing turnkey operating profit centers with regional partners, negotiating with local governments in the APAC countries, establishing OEM, and other partnerships with global integrators and distributors, and implementing regional sales and training programs. Mr. Turner is also the founder of Vocavu, an internet content company.
The South Florida Stock & Bond Club Proudly Presents Precipio Inc. (NASDAQ: PRPO) at the Boca Raton Country Club on
Tuesday, September 19, 2017. Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information on Precipio Inc., please visit www.precipiodx.com
Aug 23, 2017 - Precipio, Inc. Prices $6,000,000 Public Offering
Jul 24, 2017 - Precipio Announces Commencement of a Multi-Party Study
to Demonstrate the Impact of Academic Pathology Expertise
on Diagnostic Accuracy
Jul 11, 2017 - Precipio, Inc. (Nasdaq: PRPO) to Ring The Nasdaq Stock Market Opening Bell
Jul 05, 2017 - Precipio Announces Agreement with Clearbridge Health for Liquid Biopsy and Diagnostic Services in Asia
Jun 30, 2017 - Precipio Diagnostics and Transgenomic Complete Merger
Jun 16, 2017 - Precipio and Transgenomic Announce Experts from Yale and Harvard Joining New Scientific Advisory Board to Support Merged Company’s Growth Initiatives
Apr 20, 2017 - Precipio Renews its Exclusive Agreement with Yale School of Medicine for an Additional Five Years
ABOUT YOUR PRESENTER:
Ilan Danieli, CEO has served as Precipio's CEO since founding the company in early 2011. With over 20 years managing small and medium-size companies, some of his previous experiences include COO of Osiris, a publicly-traded company based in New York City with operations in the US, Canada, Europe and Capital Management, a multi-billion-dollar hedge fund; and in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar-Ilan University in Israel.
Please RSVP to Scott Gordon at this e-mail, firstname.lastname@example.org
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC)
at the Boca Raton Country Club on Thursday, March 15, 2018.
About Fennec Pharmaceuticals, Inc.
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutical company focused on the development of PEDMARK (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients. STS has received
Orphan Drug Designation in the US in this setting. Fennec has
completed two pediatric phase 3 studies and plans to file for
approval of PEDMARKTM in 2018.
· December 2017 - Fennec Announces Closing Of Public Offering -
The total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) was $21,153,270.
· During the third quarter, the Company announced positive results from
its Phase 3 SIOPEL 6 Study, which met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing loss without any evidence of tumor protection in patients with Standard Risk Hepatoblastoma (SR-HB)
· Company plans to pursue regulatory approvals with FDA and EU in 2018
For more information please visit: http://fennecpharma.com
ABOUT YOUR PRESENTER: ROSTISLAV RAYKOV, CEO
Mr. Raykov has served as a director of Fennec Pharma and Chief Executive Officer since July 2009. Mr. Raykov was a co-founder and portfolio manager for Alchem Investment Partners, an event driven hedge fund. Mr. Raykov also worked as a portfolio manager for Purchase Associates, an event driven hedge fund owned by John Levin & Co. He began his career as a financial analyst in the natural resources group at Bear Stearns. Mr. Raykov graduated from University of North Carolina at Chapel Hill, where he earned a Bachelor of Science degree in business administration.
5:30 pm cocktails - 6:30 pm Dinner & Presentation.
The meeting will be held at the
Boca Raton Country Club.
The location of the Boca Country Club is
17751 Boca Club Blvd. Boca Raton, FL 33487;
which is on the west side of Congress across from Costco.
(turn left before the guard gate and proceed to the parking - right lot).
Phone: (561) 447-3600
New members are welcome for our 2018 season!
Please fill out an application at the meeting
and bring $75.00 cash or check.
Made payable to:
South Florida Stock & Bond Club.
You may also mail your payment to:
South Florida Stock & Bond Club
6278 N. Federal Highway #195
Fort Lauderdale FL 33308-1916
Phone: (954) 719-1151
Copyright © South Florida Stock & Bond Club. All Rights Reserved